Clinical Trials Directory

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) or HEARTLIGHT for the Treatment of Symptomatic Atrial Fibrillation

The purpose of this study is to demonstrate the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact (HeartLight) in the treatment of atrial fibrillation by creating electrical isolation of the pulmonary veins.

Stanford is now accepting new patients for this trial.

Intervention(s):

  • device : EAS-AC (HeartLight)
  • procedure : Control Arm Ablation

Phase: Phase 3

Eligibility

Ages Eligible For Study:

18 Years - 75 Years

Inclusion Criteria

- 18 to 75 years. - paroxysmal atrial fibrillation - failure of at least one AAD - others

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Linda Norton, RN
650-725-5597
Recruiting

Footer Links: